Results 41 to 50 of about 82,297 (250)

Nanotherapies for Atherosclerosis: Targeting, Catalysis, and Energy Transduction

Advanced Healthcare Materials, EarlyView.
Atherosclerosis management is hindered by poor drug targeting and plaque heterogeneity. Nanotechnology overcomes these barriers via three core strategies: (1) target‐engineered nanocarriers that achieve lesion‐specific precision via ligand modification, biomimetic camouflage, stimuli‐responsive release, and self‐propelling nanomotors; (2) catalytic ...
Yuqi Yang, Jingguo Qu, Tonghuan Xiao, Xinyang Han, Michael Tin‐Cheung Ying   +4 more
wiley   +1 more source

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles. [PDF]

, 2017
Treatment of dyslipidemia patients with lipid-lowering drugs leads to a significant reduction in low-density lipoproteins (LDL) level and a low to moderate level of increase in high-density lipoprotein (HDL) cholesterol in plasma.
Alderete, Benjamin, Amento, Edward P, Kong, Raymond, Liu, David, Lundry, Jason, Madasamy, Shanmugavel, Robinson, J Paul, Wu, Alan HB   +7 more
core   +1 more source

Natural History of Chronic Kidney Disease in Sickle Cell Disease

American Journal of Hematology, EarlyView.
ABSTRACT Kidney complications, referred to as nephropathy, develop early in sickle cell disease (SCD). In addition to its known morbidity, abundant data show that chronic kidney disease (CKD) is associated with an increased mortality risk in SCD. Increasing evidence suggests that the natural history of SCD nephropathy is progressive. Initial glomerular
Kenneth I. Ataga
wiley   +1 more source

Redemptive benefit of atorvastatin in the risk factors of coronary artery disease [PDF]

, 2011
Cardiovascular disease, in particular coronary artery disease (CAD), is the principal cause of mortality in developed countries. The classical acute phase protein, C-reactive protein (CRP) is an exquisitely sensitive systemic marker of disease ...
Jayaraman Gowri , Arumugam Vijaya Anand , Shanmugam Achiraman , Govindha Raj Archunan , Subramaniyam Kalavathy , Palanisamy Sampath Kumar , Kalaiyarasan Vijaya Kumar Int J Cur Biomed Phar Res.
core  

Efficacy and Safety of Ezetimibe Added to Atorvastatin Versus Atorvastatin Uptitration or Switching to Rosuvastatin in Patients With Primary Hypercholesterolemia [PDF]

, 2013
Hypercholesterolemic patients (n = 1,547) at high atherosclerotic cardiovascular disease risk with low-density lipoprotein cholesterol (LDL-C) levels 65100 and 64160 mg/dl while treated with atorvastatin 10 mg/day entered a multicenter, randomized ...
Averna, M., Bays, H., Brudi, P., De Pellegrin, A., Farnier, M., Giezek, H., Lee, R., Lowe, R., Majul, C., Muller Wieland, D., Triscari, J.   +10 more
core   +1 more source

Optimization of pharmaceutical research and development by early‐phase assessment of investigational medicinal products

British Journal of Clinical Pharmacology, EarlyView.
Small and mid‐sized pharmaceutical innovators often have limited in‐house health economics and market access expertise, and may struggle to align development strategies of investigational medicinal products with health system needs and payer expectations.
Zoltán Kaló, Attila Imre, Gábor Varga, Sándor Kovács, György Tímár, Balázs Nagy   +5 more
wiley   +1 more source

Clinical pharmacology and prescribing education: An updated medical school curriculum from the British Pharmacological Society

British Journal of Clinical Pharmacology, EarlyView.
Aims Prescribing is a complex, essential skill that doctors must acquire to practice medicine safely and effectively. The British Pharmacological Society has historically provided a core curriculum to guide clinical pharmacology and prescribing education in UK medical schools.
Dagan O. Lonsdale, Clare Guilding, Jennifer Koenig, Michael Okorie, Reecha Sofat, Simon Maxwell   +5 more
wiley   +1 more source

Atorvastatin before percutaneous coronary intervention: A systematic review and meta-analysis.

PLoS ONE
Atorvastatin is widely recommended for long-term secondary prevention in STEMI patients with no contraindication. Although high-dose atorvastatin has been shown to reduce important patient outcomes such as MACE, there is still doubt that high-dose ...
Mariano García-Campa, Ramiro Flores-Ramírez, Sabrina Rojo-Garza, Edgar Francisco Carrizales-Sepúlveda, Diego Regalado-Ceballos, Raúl Reyes-Araiza, Neri Álvarez-Villalobos, Rene Rodríguez-Gutiérrez, José Ramón Azpiri-López   +8 more
doaj   +1 more source

A Validated Reversed-Phase HPLC Method for the Determination of Atorvastatin Calcium in Tablets [PDF]

, 2014
A Reversed-Phase Liquid Chromatographic (RP-LC) assay method was developed for the quantitative determination of atorvastatin calcium in the presence of its degradation products.
Ferello, L., Repetto, M. F., Segall, Adriana Ines, Simionato, Laura Daniela, Stamer. S., Zubata, P. D.   +5 more
core  

The quantitative impact of metabolism‐inhibiting drugs on the occurrence of adverse drug reactions—A backward selection approach

British Journal of Clinical Pharmacology, EarlyView.
Abstract Aim The quantitative effect of several inhibitory drugs on the development of adverse drug reactions (ADRs) is currently difficult to estimate. Our aim was to identify metabolic pathways, which, when inhibited, increase the risk for certain ADRs, and to use this system to consider comedication at individual level. Methods Data of a prospective
Judith Berres, Justyna Wozniak, Hannah Fölsch, Anja Knueppel‐Ruppert, Verena Graeff, Andrea Kriegisch‐Stumpf, Harald Dormann, Julia C. Stingl, Katja S. Just   +8 more
wiley   +1 more source